Fosfomycin: A Novel Epoxide Antimicrobial

Video
Conference|ID Week

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a novel antimicrobial. She also shares what the drug’s unique mechanism of action is.

Recent Videos
Related Content
FDA Accepts NDA for Zoliflodacin, Oral Antibiotic For Uncomplicated Gonorrhea

FDA Accepts NDA for Zoliflodacin, Oral Antibiotic For Uncomplicated Gonorrhea

Sophia Abene
June 10th 2025
Article
Can Diagnostics Aid in Alleviating Antimicrobial Resistance and Sepsis?

Can Diagnostics Aid in Alleviating Antimicrobial Resistance and Sepsis?

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc
May 16th 2025
Podcast
Oral Cephalosporins Safe, Effective For Step-Down Therapy For Gram-Negative Bloodstream Infections

Oral Cephalosporins Safe, Effective For Step-Down Therapy For Gram-Negative Bloodstream Infections

John Parkinson
May 29th 2025
Article
From Pathogen to Infectious Disease Diagnosis: Test Determines Between Bacterial and Viral Infections in 15 Minutes

From Pathogen to Infectious Disease Diagnosis: Test Determines Between Bacterial and Viral Infections in 15 Minutes

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc ;Eran Eden, PhD
April 14th 2025
Podcast
Investigational cUTI Antibiotic Meets Endpoint, Phase 3 Study Stopped Early

Investigational cUTI Antibiotic Meets Endpoint, Phase 3 Study Stopped Early

John Parkinson
May 28th 2025
Article
Company Receives NIH Grant For Novel Investigational Antibiotic to Combat ‘Super Gonorrhea’

Company Receives NIH Grant For Novel Investigational Antibiotic to Combat ‘Super Gonorrhea’

John Parkinson
May 27th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.